Skip to main content
Erschienen in: Tumor Biology 5/2014

01.05.2014 | Research Article

A genetic variant in microRNA target site of TGF-β signaling pathway increases the risk of colorectal cancer in a Chinese population

verfasst von: Jing Gong, Na Shen, Hong-Mei Zhang, Rong Zhong, Wei Chen, Xiaoping Miao, An-Yuan Guo

Erschienen in: Tumor Biology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Evidence shows that single-nucleotide polymorphisms in microRNA (miRNA) target sites can create, destroy, or modify the miRNA/mRNA binding, therefore modulating gene expression and affecting cancer susceptibility. The transforming growth factor-β (TGF-β) signaling pathway plays a pivotal role in tumor initiation and progression. Intriguingly, recent advances of genome-wide association studies have identified multiple risk loci in this pathway to be associated with risk of colorectal cancer (CRC). To test the hypothesis that genetic variants in miRNA target sites in genes of the TGF-β signaling pathway may also be associated with CRC risk, we first systematically scanned the single-nucleotide polymorphisms (SNPs) in genes of TGF-β signaling pathway which potentially affect the miRNA/mRNA bindings. Through a series of filters, we narrowed down these candidates to four SNPs. Then, we conducted a case–control study with 600 CRC patients and 638 controls in Han Chinese population. We observed that compared with A carriers (AA + AG), the GG genotype of rs12997:ACVR1 is associated with a significantly higher risk of CRC (OR = 1.52, 95 % confidence interval (95 % CI) = 1.04–2.21, P = 0.031), particularly in nonsmokers with a higher OR of 1.63 (95 % CI = 1.04–2.55, P = 0.032). Our study suggested that SNPs in miRNA target sites could contribute to the likelihood of CRC susceptibility and emphasized the important role of polymorphisms at miRNA-regulatory elements in carcinogenesis.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Zurück zum Zitat Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21.PubMedPubMedCentral Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21.PubMedPubMedCentral
3.
Zurück zum Zitat Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res. 1997;57:4787–94.PubMed Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res. 1997;57:4787–94.PubMed
4.
Zurück zum Zitat Limsui D, Limburg PJ. Cigarette smoking and colorectal cancer risk: a burning issue. Gastroenterology. 2008;135:704–5.CrossRefPubMed Limsui D, Limburg PJ. Cigarette smoking and colorectal cancer risk: a burning issue. Gastroenterology. 2008;135:704–5.CrossRefPubMed
5.
Zurück zum Zitat Peng XE, Jiang YY, Shi XS, Hu ZJ. Nqo1 609C > T polymorphism interaction with tobacco smoking and alcohol drinking increases colorectal cancer risk in a Chinese population. Gene. 2013;521:105–10.CrossRefPubMed Peng XE, Jiang YY, Shi XS, Hu ZJ. Nqo1 609C > T polymorphism interaction with tobacco smoking and alcohol drinking increases colorectal cancer risk in a Chinese population. Gene. 2013;521:105–10.CrossRefPubMed
6.
Zurück zum Zitat Zhong R, Liu L, Zou L, Sheng W, Zhu B, Xiang H, et al. Genetic variations in the tgfbeta signaling pathway, smoking and risk of colorectal cancer in a chinese population. Carcinogenesis. 2013;34:936–42.CrossRefPubMed Zhong R, Liu L, Zou L, Sheng W, Zhu B, Xiang H, et al. Genetic variations in the tgfbeta signaling pathway, smoking and risk of colorectal cancer in a chinese population. Carcinogenesis. 2013;34:936–42.CrossRefPubMed
7.
Zurück zum Zitat Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. New Engl J Med. 2000;343:78–85.CrossRefPubMed Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. New Engl J Med. 2000;343:78–85.CrossRefPubMed
8.
Zurück zum Zitat Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nature Rev Genet. 2009;10:353–8.CrossRefPubMed Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nature Rev Genet. 2009;10:353–8.CrossRefPubMed
9.
Zurück zum Zitat Yang Y, Wang F, Shi C, Zou Y, Qin H, Ma Y. Cyclin d1 g870a polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case–control studies. PloS One. 2012;7:e36813.CrossRefPubMedPubMedCentral Yang Y, Wang F, Shi C, Zou Y, Qin H, Ma Y. Cyclin d1 g870a polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case–control studies. PloS One. 2012;7:e36813.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals Oncol. 2012;23:1207–13.CrossRef Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals Oncol. 2012;23:1207–13.CrossRef
11.
Zurück zum Zitat Castro FA, Forsti A, Buch S, Kalthoff H, Krauss C, Bauer M, et al. Tlr-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer. 2011;47:1203–10.CrossRefPubMed Castro FA, Forsti A, Buch S, Kalthoff H, Krauss C, Bauer M, et al. Tlr-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer. 2011;47:1203–10.CrossRefPubMed
12.
Zurück zum Zitat Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nature Genet. 2008;40:1426–35.CrossRefPubMed Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nature Genet. 2008;40:1426–35.CrossRefPubMed
13.
14.
Zurück zum Zitat Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23:2078–93.CrossRefPubMed Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23:2078–93.CrossRefPubMed
15.
16.
Zurück zum Zitat Bierie B, Moses HL. Tumour microenvironment: TGF beta: the molecular Jekyll and Hyde of cancer. Nature Rev Cancer. 2006;6:506–20.CrossRefPubMed Bierie B, Moses HL. Tumour microenvironment: TGF beta: the molecular Jekyll and Hyde of cancer. Nature Rev Cancer. 2006;6:506–20.CrossRefPubMed
17.
Zurück zum Zitat Ku JL, Park SH, Yoon KA, Shin YK, Kim KH, Choi JS, et al. Genetic alterations of the TGF-beta signaling pathway in colorectal cancer cell lines: a novel mutation in SMAD3 associated with the inactivation of TGF-beta-induced transcriptional activation. Cancer Lett. 2007;247:283–92.CrossRefPubMed Ku JL, Park SH, Yoon KA, Shin YK, Kim KH, Choi JS, et al. Genetic alterations of the TGF-beta signaling pathway in colorectal cancer cell lines: a novel mutation in SMAD3 associated with the inactivation of TGF-beta-induced transcriptional activation. Cancer Lett. 2007;247:283–92.CrossRefPubMed
18.
Zurück zum Zitat Xu Y, Pasche B. Tgf-beta signaling alterations and susceptibility to colorectal cancer. Human molecular genetics 2007;16 Spec No 1:R14-20 Xu Y, Pasche B. Tgf-beta signaling alterations and susceptibility to colorectal cancer. Human molecular genetics 2007;16 Spec No 1:R14-20
19.
Zurück zum Zitat Fukushima T, Mashiko M, Takita K, Otake T, Endo Y, Sekikawa K, et al. Mutational analysis of tgf-beta type ii receptor, smad2, smad3, smad4, smad6 and smad7 genes in colorectal cancer. J Exp Clin Cancer Res. 2003;22:315–20.PubMed Fukushima T, Mashiko M, Takita K, Otake T, Endo Y, Sekikawa K, et al. Mutational analysis of tgf-beta type ii receptor, smad2, smad3, smad4, smad6 and smad7 genes in colorectal cancer. J Exp Clin Cancer Res. 2003;22:315–20.PubMed
20.
Zurück zum Zitat Bartel DP. MicrorNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed Bartel DP. MicrorNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed
22.
Zurück zum Zitat Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.CrossRefPubMed Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.CrossRefPubMed
23.
Zurück zum Zitat Wang G, van der Walt JM, Mayhew G, Li YJ, Zuchner S, Scott WK, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Human Genet. 2008;82:283–9.CrossRef Wang G, van der Walt JM, Mayhew G, Li YJ, Zuchner S, Scott WK, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Human Genet. 2008;82:283–9.CrossRef
24.
Zurück zum Zitat Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, et al. A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer. Clinical Cancer Res. 2011;17:7723–31.CrossRef Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, et al. A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer. Clinical Cancer Res. 2011;17:7723–31.CrossRef
25.
Zurück zum Zitat Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Human Genet. 2007;81:405–13.CrossRef Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Human Genet. 2007;81:405–13.CrossRef
26.
Zurück zum Zitat Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat. 2012;33:254–63.CrossRefPubMed Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat. 2012;33:254–63.CrossRefPubMed
27.
Zurück zum Zitat Renlund N, O’Neill FH, Zhang L, Sidis Y, Teixeira J. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor. J Endocrinol. 2007;195:95–103.CrossRefPubMed Renlund N, O’Neill FH, Zhang L, Sidis Y, Teixeira J. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor. J Endocrinol. 2007;195:95–103.CrossRefPubMed
28.
Zurück zum Zitat Wu TC, Jih MH, Wang L, Wan YJ. Expression of activin receptor II and IIB mRNA isoforms in mouse reproductive organs and oocytes. Mol Reprod Dev. 1994;38:9–15.CrossRefPubMed Wu TC, Jih MH, Wang L, Wan YJ. Expression of activin receptor II and IIB mRNA isoforms in mouse reproductive organs and oocytes. Mol Reprod Dev. 1994;38:9–15.CrossRefPubMed
29.
Zurück zum Zitat Donaldson CJ, Mathews LS, Vale WW. Molecular cloning and binding properties of the human type II activin receptor. Biochem Biophys Res Comm. 1992;184:310–6.CrossRefPubMed Donaldson CJ, Mathews LS, Vale WW. Molecular cloning and binding properties of the human type II activin receptor. Biochem Biophys Res Comm. 1992;184:310–6.CrossRefPubMed
30.
Zurück zum Zitat Eresen Yazicioglu C, Karatosun V, Kizildag S, Ozsoylu D, Kavukcu S. Acvr1 Gene mutations in four Turkish patients diagnosed as fibrodysplasia ossificans progressiva. Gene. 2013;515:444–6.CrossRefPubMed Eresen Yazicioglu C, Karatosun V, Kizildag S, Ozsoylu D, Kavukcu S. Acvr1 Gene mutations in four Turkish patients diagnosed as fibrodysplasia ossificans progressiva. Gene. 2013;515:444–6.CrossRefPubMed
31.
Zurück zum Zitat Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, et al. A recurrent mutation in the bmp type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genet. 2006;38:525–7.CrossRefPubMed Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, et al. A recurrent mutation in the bmp type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genet. 2006;38:525–7.CrossRefPubMed
32.
Zurück zum Zitat Ambrosio EP, Drigo SA, Bergamo NA, Rosa FE, Bertonha FB, de Abreu FB, et al. Recurrent copy number gains of ACVR1 and corresponding transcript overexpression are associated with survival in head and neck squamous cell carcinomas. Histopathology. 2011;59:81–9.CrossRefPubMed Ambrosio EP, Drigo SA, Bergamo NA, Rosa FE, Bertonha FB, de Abreu FB, et al. Recurrent copy number gains of ACVR1 and corresponding transcript overexpression are associated with survival in head and neck squamous cell carcinomas. Histopathology. 2011;59:81–9.CrossRefPubMed
33.
Zurück zum Zitat Wiley LA, Rajagopal R, Dattilo LK, Beebe DC. The tumor suppressor gene TRP53 protects the mouse lens against posterior subcapsular cataracts and the bmp receptor ACVR1 acts as a tumor suppressor in the lens. Disease Models Mech. 2011;4:484–95.CrossRef Wiley LA, Rajagopal R, Dattilo LK, Beebe DC. The tumor suppressor gene TRP53 protects the mouse lens against posterior subcapsular cataracts and the bmp receptor ACVR1 acts as a tumor suppressor in the lens. Disease Models Mech. 2011;4:484–95.CrossRef
34.
Zurück zum Zitat Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010;70:2789–98.CrossRefPubMedPubMedCentral Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010;70:2789–98.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Zhao X, Ye Q, Xu K, Cheng J, Gao Y, Li Q, et al. Single-nucleotide polymorphisms inside microrna target sites influence the susceptibility to type 2 diabetes. J Human Genet. 2013;58:135–41.CrossRef Zhao X, Ye Q, Xu K, Cheng J, Gao Y, Li Q, et al. Single-nucleotide polymorphisms inside microrna target sites influence the susceptibility to type 2 diabetes. J Human Genet. 2013;58:135–41.CrossRef
Metadaten
Titel
A genetic variant in microRNA target site of TGF-β signaling pathway increases the risk of colorectal cancer in a Chinese population
verfasst von
Jing Gong
Na Shen
Hong-Mei Zhang
Rong Zhong
Wei Chen
Xiaoping Miao
An-Yuan Guo
Publikationsdatum
01.05.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1562-9

Weitere Artikel der Ausgabe 5/2014

Tumor Biology 5/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.